By Fredrik Arnold : Results from here , as verified using Yahoo Finance data for small, mid, & large cap healthcare sector stocks, as of market closing prices August 15 compared with analyst mean target price results one year hence showed Kindred Healthcare, Inc. (NYSE: KND ), flaunted a 30.33% ...
Aug 14 (Reuters) - Active Biotech : * Active biotech's partner teva initiates a laquinimod clinical trial in
Cubist acquired Adolor Corp. in 2011 and Calixa Therapeutics in 2010. Teva had challenged Cubicin's patents, but the two firms reached a licensing agreement that will enable Teva to sell generic Cubicin in early 2018. This news was a big win for
PAGEBREAK> At the current time, the Appleseed Fund’s equity portfolio owns healthcare stocks such as Teva Pharmaceuticals ( TEVA ), Novartis (NVS), and PDI Inc. (PDII) due in part to our view that healthcare will continue to grow faster
Actavis Standard marks for shareholder stewardship. Historically, Actavis has avoided an aggressive acquisition strategy like Teva and Mylan, but management has proved adept at finding niche generic opportunities, including Lipitor, Lovenox, and Concerta
outlook of $3.25 to $3.45 due to our estimate of an ongoing delay in key product launches, particularly a generic version of Teva ’s Copaxone. We have made no major changes to our longer-term forecast, including the integration of Abbott’s non
The company's stock has handily outperformed the S&P 500 over the last five years and has crushed one of its peers (NYSE: TEVA ) in that time while underperforming Actavis (NYSE: ACT ) in that time. MYL Total Return Price data by YCharts In this article
very attractive takeover candidate, but we do not incorporate a takeover premium into our valuation. Large generic firms ( Teva , Actavis, Mylan) have repeatedly expressed interest in acquisitions and a desire to grow their presence in difficult-to
By Cory Renauer : While most promising young biotechs devote all resources to development of new drugs, Momenta Pharmaceuticals (NASDAQ: MNTA ) is adopting a fairly unusual strategy of aiming for the middle. Its plan for developing biosimilars -- generic versions of complex biologics -- yielded ...
By Alexander Maxwell : It can be very hard for investors to be able to keep track of all of the different events going on within the biotech world, with clinical trial results, and FDA decisions happening rather frequently. The purpose of this article is to hopefully make investor's lives a little